Cadila Healthcare is currently trading at Rs. 349.95, up by 0.80 points or 0.23% from its previous closing of Rs. 349.15 on the BSE.
The scrip opened at Rs. 350.00 and has touched a high and low of Rs. 352.10 and Rs. 348.40 respectively. So far 11858 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 429.45 on 01-Nov-2016 and a 52 week low of Rs. 295.50 on 18-Jan-2016.
Last one week high and low of the scrip stood at Rs. 364.00 and Rs. 346.10 respectively. The current market cap of the company is Rs. 35805.40 crore.
The promoters holding in the company stood at 74.79%, while institutions and non-institutions held 17.18% and 8.03% respectively.
Cadila Healthcare, a global pharmaceuticals company, and its subsidiary Zydus Pharmaceuticals (USA) Inc., a leading generic pharmaceutical company in the United States, have finalized an agreement with Kowa Company, Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, to settle all outstanding patent litigation related to Livalo (pitavastatin calcium) tablets.
Under the terms of the agreement, Kowa and Nissan grants Zydus a license to market Zydus’ generic version of Livalo beginning on May 2, 2023, or earlier under certain circumstances. Other terms of the settlement were not disclosed.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 19,500 people worldwide and is dedicated to creating healthier communities globally.
